Serum anti-müllerian hormone levels in patients with epithelial ovarian cancer

International Journal of Endocrinology

Volumn 2013, Issue , 2013, Pages

  Walentowicz, Pawel ^a   Sadlecki, Pawel ^a   Krintus, Magdalena ^a   Sypniewska, Grazyna ^a   Mankowska Cyl, Aneta ^a   Grabiec, Marek ^a   Walentowicz Sadlecka, Malgorzata ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

MUELLERIAN INHIBITING FACTOR;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CORRELATION ANALYSIS; CYTOREDUCTIVE SURGERY; ELISA KIT; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; SURVIVAL RATE;

EID: 84883166338     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2013/517239     Document Type: Article

References (27)

1. Siegel R., Naishadham D., Jemal A., Cancer statistics, 2012. CA Cancer Journal for Clinicians 2012 62 1 10 29 2-s2.0-84855792427 10.3322/caac.20138
2. Park Y., Lee J.-H., Hong D. J., Lee E. Y., Kim H.-S., Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases. Clinical Biochemistry 2011 44 10-11 884 888 2-s2.0-79958817864 10.1016/j.clinbiochem.2011.04.011
3. Walentowicz-Sadlecka M., Grabiec M., Sadlecki P., Gotowska M., Walentowicz P., Krintus M., Mankowska-Cyl A., Sypniewska G. 25(OH)D3 in patients with ovarian cancer and its correlation with survival. Clinical Biochemistry 2012 45 1568 1572 10.1016/j.clinbiochem.2012.07.110
4. La Marca A., Stabile G., Carducci Artenisio A., Volpe A., Serum anti-Mullerian hormone throughout the human menstrual cycle. Human Reproduction 2006 21 12 3103 3107 2-s2.0-33751368487 10.1093/humrep/del291
5. Alebić M. Š., Stojanović N., Zuvić-Butorac M., The IVF outcome counseling based on the model combining DHEAS and age in patients with low AMH prior to the first cycle of GnRH antagonist protocol of ovarian stimulation. International Journal of Endocrinology 2013 2013 637919 10.1155/2013/637919
6. Rey R., Josso N., Regulation of testicular anti-Mullerian hormone secretion. European Journal of Endocrinology 1996 135 2 144 152 2-s2.0-0029831894
7. Behringer R. R., Finegold M. J., Cate R. L., Müllerian-inhibiting substance function during mammalian sexual development. Cell 1994 79 3 415 425 2-s2.0-0028172159
8. Lee M. M., Donahoe P. K., Hasegawa T., Müllerian inhibiting substance in humans: normal levels from infancy to adulthood. The Journal of Clinical Endocrinology & Metabolism 1996 81 2 571 576 10.1210/jc.81.2.571
9. Brougham M. F., Crofton P. M., Johnson E. J., Evans N., Anderson R. A., Wallace W. H., Anti-Müllerian hormone is a marker of gonadotoxicity in pre- and postpubertal girls treated for cancer: a prospective study. The Journal of Clinical Endocrinology & Metabolism 2012 97 2059 2067 10.1210/jc.2011-3180
10. Cook C. L., Siow Y., Taylor S., Fallat M. E., Serum mullerian-inhibiting substance levels during normal menstrual cycles. Fertility and Sterility 2000 73 4 859 861 2-s2.0-0033624843 10.1016/S0015-0282(99)00639-1
11. Streuli I., Fraisse T., Chapron C., Bijaoui G., Bischof P., de Ziegler D., Clinical uses of anti-Müllerian hormone assays: pitfalls and promises. Fertility and Sterility 2009 91 1 226 230 2-s2.0-58049191501 10.1016/j.fertnstert.2007.10.067
12. Baarends W. M., Uilenbroek J. T. J., Kramer P., Hoogerbrugge J. W., Van Leeuwen E. C. M., Themmen A. P. N., Grootegoed J. A., Anti-Mullerian hormone and anti-Mullerian hormone type II receptor messenger ribonucleic acid expression in rat ovaries during postnatal development, the estrous cycle, and gonadotropin-induced follicle growth. Endocrinology 1995 136 11 4951 4962 2-s2.0-0028973297
13. Shi J., Yoshimo Y., Oshuga Y., Bone morhogenetic protien-6 stimulates gene expression of follicle stimulating hormone receptor, inhibin/activin β subunit and anti-Müllerian hormone in human granulose cells. Fertility and Sterility 2009 92 1794 1798 10.1016/j.fertnstert.2009.05.004
14. de Vet A., Laven J. S. E., de Jong F. H., Themmen A. P. N., Fauser B. C. J. M., Antimüllerian hormone serum levels: a putative marker for ovarian aging. Fertility and Sterility 2002 77 2 357 362 2-s2.0-0036155640 10.1016/S0015-0282(01)02993-4
15. Fanchin R., Schonäuer L. M., Righini C., Guibourdenche J., Frydman R., Taieb J., Serum anti-Müllerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Human Reproduction 2003 18 2 323 327 2-s2.0-0037323643 10.1093/humrep/deg042
16. van Rooij I. A. J., den Tonkelaar I., Broekmans F. J. M., Looman C. W. N., Scheffer G. J., de Jong F. H., Themmen A. P. N., te Velde E. R., Anti-Müllerian hormone is a promising predictor for the occurrence of the menopausal transition. Menopause 2004 11 6 601 606 2-s2.0-14844362723 10.1097/01.GME.0000123642.76105.6E
17. La Marca A., Sighinolfi G., Radi D., Argento C., Baraldi E., Artenisio A. C., Stabile G., Volpe A., Anti-Müllerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Human Reproduction Update 2009 16 2 113 130 2-s2.0-77949454760 10.1093/humupd/dmp036
18. Broer S., Mol B. W., Dolleman M., Fauser B., Broekmans J. M., The role of anti-Müllerian hormone assessment in assisted reproductive technology outcome. Current Opinion in Obstetrics and Gynecology 2010 22 193 201 10.1097/GCO.0b013e3283384911
19. Nakhuda G. S., Chu M. C., Wang J. G., Sauer M. V., Lobo R. A., Elevated serum müllerian-inhibiting substance may be a marker for ovarian hyperstimulation syndrome in normal women undergoing in vitro fertilization. Fertility and Sterility 2006 85 5 1541 1543 2-s2.0-33646106095 10.1016/j.fertnstert.2005.10.052
20. Lie Fong S., Lugtenburg P. J., Schipper I., Themmen A. P. N., de Jong F. H., Sonneveld P., Laven J. S. E., Anti-müllerian hormone as a marker of ovarian function in women after chemotherapy and radiotherapy for haematological malignancies. Human Reproduction 2008 23 3 674 678 2-s2.0-40749097721 10.1093/humrep/dem392
21. Giuseppe L., Attilio G., Edoardo D. N., Loredana G., Cristina L., Vincenzo L., Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD). Hematology 2007 12 2 141 147 2-s2.0-34247183723 10.1080/10245330600954072
22. Rey R., Sabourin J. C., Venara M., Anti-Müllerian hormone is specific marker of sertoli -and granulose-cell origin in gonadal tumors. Human Pathology 2000 31 1202 1203 10.1053/hupa.2000.18498
23. Gustafson M. L., Lee M. M., Scully R. E., Müllerian inhibiting substance as a marker for ovarian sex cord tumor. The New England Journal of Medicine 1992 326 1820 1826
24. Seifer D. B., Baker V. L., Leader B., Age-specific serum anti-Müllerian hormone values for 17,120 women presenting to fertility centers within the United States. Fertility and Sterility 2011 95 2 747 750 2-s2.0-78751585466 10.1016/j.fertnstert.2010.10.011
25. Dubeau L., The cell of origin of ovarian epithelial tumours. The Lancet Oncology 2008 9 12 1191 1197 2-s2.0-56749103412 10.1016/S1470-2045(08)70308-5
26. Masiakos P. T., MacLaughlin D. T., Maheswaran S., Teixeira J., Fuller A. F. Jr., Shah P. C., Kehas D. J., Kenneally M. K., Dombkowski D. M., Ha T. U., Preffer F. I., Donahoe P. K., Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS. Clinical Cancer Research 1999 5 11 3488 3499 2-s2.0-0032753468
27. Stephen A. E., Pearsall L. A., Christian B. P., Donahoe P. K., Vacanti J. P., MacLaughlin D. T., Highly purified Müllerian inhibiting substance inhibits human ovarian cancer in vivo. Clinical Cancer Research 2002 8 8 2640 2646 2-s2.0-0036023430